GlassScriptPhysician profile
Melissa Summerlin
NPI 1043519671
$7,411.10
in general payments reported to CMS, 2019-2025
57 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $958 · 2023: $2,136 · 2024: $1,516 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Education: $26.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.78 |
| Education | $26.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $854.62 | 2023-2025 | Cabometyx |
| Celgene Corporation | $778.03 | 2021-2025 | Reblozyl |
| Abbvie INC. | $404.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $399.36 | 2021-2025 | Lynparza, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $329.48 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| Pfizer INC. | $317.12 | 2021-2025 | |
| Seagen INC. | $296.69 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Novartis Pharmaceuticals Corporation | $287.03 | 2021-2025 | |
| Incyte Corporation | $256.58 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $247.09 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.89 | 2021-2024 | Opdivo |
| Glaxosmithkline, LLC. | $224.71 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Genzyme Corporation | $208.22 | 2021-2025 | |
| Daiichi Sankyo INC. | $188.55 | 2021-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $182.22 | 2022-2024 | Libtayo |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $153.81 | 2022-2025 | Venclexta, Tecentriq, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $130.58 | 2021-2025 | Fruzaqla, Ninlaro |
| Gilead Sciences, INC. | $124.36 | 2021-2025 | Trodelvy |
| Myriad Genetic Laboratories, INC. | $110.07 | 2024 | Myrisk |
| Amgen INC. | $106.24 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $103.28 | 2021-2023 | |
| Sobi, INC | $91.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $91.66 | 2021-2025 | Keytruda, Welireg |
| Karyopharm Therapeutics INC. | $79.44 | 2021-2025 | Xpovio |
| Astellas Pharma US INC | $77.14 | 2021-2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $71.98 | 2021-2023 | Somatuline Depot, Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $64.09 | 2025 | |
| Adaptive Biotechnologies Corporation | $59.58 | 2023-2025 | Clonoseq |
| Pharmaessentia USA Corporation | $57.42 | 2022-2025 | Besremi |
| Blueprint Medicines Corporation | $56.28 | 2021-2022 | |
| Array Biopharma INC | $55.42 | 2021-2024 | Tukysa, Braftovi, Mektovi |
| Taiho Oncology, INC. | $52.53 | 2022-2023 | |
| Coherus Oncology, INC. | $51.01 | 2021-2024 | |
| Puma Biotechnology, INC. | $49.49 | 2021-2023 | |
| Beone Medicines USA, INC. | $43.82 | 2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $42.55 | 2023-2024 | Rezlidhia, Tavalisse |
| Agios Pharmaceuticals, INC. | $42.13 | 2024-2025 | Pyrukynd |
| Beigene USA, INC. | $40.62 | 2023-2024 | Brukinsa |
| Stemline Therapeutics INC. | $38.91 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $35.56 | 2021-2022 | |
| Epizyme, INC. | $34.77 | 2021 | |
| Alexion Pharmaceuticals, INC. | $34.49 | 2022-2024 | Ultomiris |
| Lilly USA, LLC | $32.14 | 2021-2025 | Verzenio, Jaypirca |
| Genmab U.S., INC. | $26.23 | 2023 | Epkinly |
| Sumitomo Pharma America, INC. | $24.81 | 2024 | Orgovyx |
| Dova Pharmaceuticals | $22.18 | 2021 | |
| Legend Biotech USA INC. | $20.95 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $19.81 | 2021 | |
| Mirati Therapeutics, INC. | $19.73 | 2024 | Krazati |
| Immunocore Limited | $19.42 | 2024 | Kimmtrak |
| Servier Pharmaceuticals LLC | $18.91 | 2024 | |
| Corcept Therapeutics | $18.50 | 2025 | Korlym |
| Adc Therapeutics America, INC. | $17.73 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $16.81 | 2022 | |
| Morphosys, US INC. | $16.30 | 2021 | |
| Kite Pharma, INC. | $16.01 | 2023 | |
| Acceleron Pharma, INC. | $14.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Summerlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.